<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26813123</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-6190</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2016</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current neuropharmacology</Title>
          <ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alzheimer's disease: Targeting the Cholinergic System.</ArticleTitle>
        <Pagination>
          <StartPage>101</StartPage>
          <EndPage>115</EndPage>
          <MedlinePgn>101-15</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Acetylcholine (ACh) has a crucial role in the peripheral and central nervous systems. The enzyme choline acetyltransferase (ChAT) is responsible for synthesizing ACh from acetyl-CoA and choline in the cytoplasm and the vesicular acetylcholine transporter (VAChT) uptakes the neurotransmitter into synaptic vesicles. Following depolarization, ACh undergoes exocytosis reaching the synaptic cleft, where it can bind its receptors, including muscarinic and nicotinic receptors. ACh present at the synaptic cleft is promptly hydrolyzed by the enzyme acetylcholinesterase (AChE), forming acetate and choline, which is recycled into the presynaptic nerve terminal by the high-affinity choline transporter (CHT1). Cholinergic neurons located in the basal forebrain, including the neurons that form the nucleus basalis of Meynert, are severely lost in Alzheimer's disease (AD). AD is the most ordinary cause of dementia affecting 25 million people worldwide. The hallmarks of the disease are the accumulation of neurofibrillary tangles and amyloid plaques. However, there is no real correlation between levels of cortical plaques and AD-related cognitive impairment. Nevertheless, synaptic loss is the principal correlate of disease progression and loss of cholinergic neurons contributes to memory and attention deficits. Thus, drugs that act on the cholinergic system represent a promising option to treat AD patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ferreira-Vieira</LastName>
            <ForeName>Talita H</ForeName>
            <Initials>TH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guimaraes</LastName>
            <ForeName>Isabella M</ForeName>
            <Initials>IM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Flavia R</ForeName>
            <Initials>FR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ribeiro</LastName>
            <ForeName>Fabiola M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. fmribeiro@icb.ufmg.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Neuropharmacol</MedlineTA>
        <NlmUniqueID>101157239</NlmUniqueID>
        <ISSNLinking>1570-159X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011950" MajorTopicYN="N">Receptors, Cholinergic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26813123</ArticleId>
        <ArticleId IdType="pmc">PMC4787279</ArticleId>
        <ArticleId IdType="doi">10.2174/1570159x13666150716165726</ArticleId>
        <ArticleId IdType="pii">CN-EPUB-68917</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Loewi O.  Über humerole übertragbarkeit der herznervenwirkung. I
Mitteilung Pflugers Arch., 1921, 189, 239-242. 10.
1007/BF01738910 . 1921. </Citation>
        </Reference>
        <Reference>
          <Citation>Armstrong D.M., Saper C.B., Levey A.I., Wainer B. h., Terry R.D. Distribution of cholinergic neurons in rat brain: demonstrated by the immunocytochemical localization of choline acetyltransferase. 1983. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.902160106</ArticleId>
            <ArticleId IdType="pubmed">6345598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolf N.J., Butcher L.L. Cholinergic systems mediate action from movement to higher consciousness. Behav. Brain Res. 2011;221(2):488–498. doi: 10.1016/j.bbr.2009.12.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2009.12.046</ArticleId>
            <ArticleId IdType="pubmed">20060422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houser C.R., Crawford G.D., Barber R.P., Salvaterra P.M., Vaughn J.E. Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res. 1983;266(1):97–119. doi: 10.1016/0006-8993(83)91312-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(83)91312-4</ArticleId>
            <ArticleId IdType="pubmed">6850348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura H., McGeer P.L., Peng J.H., McGeer E.G. The central cholinergic system studied by choline acetyltransferase immunohistochemistry in the cat. J. Comp. Neurol. 1981;200(2):151–201. doi: 10.1002/cne.902000202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.902000202</ArticleId>
            <ArticleId IdType="pubmed">7287919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. 2003;446(1):17–29. doi: 10.1007/s00424-002-0999-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00424-002-0999-2</ArticleId>
            <ArticleId IdType="pubmed">12690458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolf N.J. Cholinergic systems in mammalian brain and spinal cord. 1991. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0301-0082(91)90006-M</ArticleId>
            <ArticleId IdType="pubmed">1763188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bucci D.J., Holland P.C., Gallagher M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J. Neurosci. 1998;18(19):8038–8046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793033</ArticleId>
            <ArticleId IdType="pubmed">9742170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voytko M.L., Olton D.S., Richardson R.T., Gorman L.K., Tobin J.R., Price D.L. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci. 1994;14(1):167–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6576852</ArticleId>
            <ArticleId IdType="pubmed">8283232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pepeu G., Giovannini M.G., Bracco L. Effect of cholinesterase inhibitors on attention. Chem. Biol. Interact. 2013;203(1):361–364. doi: 10.1016/j.cbi.2012.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2012.09.016</ArticleId>
            <ArticleId IdType="pubmed">23047023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bracco L., Bessi V., Padiglioni S., Marini S., Pepeu G. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer’s disease patients. J. Alzheimers Dis. 2014;40(3):737–742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24577458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fine A., Hoyle C., Maclean C.J., Levatte T.L., Baker H.F., Ridley R.M. Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys. Neuroscience. 1997;81(2):331–343. doi: 10.1016/S0306-4522(97)00208-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0306-4522(97)00208-X</ArticleId>
            <ArticleId IdType="pubmed">9300425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miranda M.I., Bermúdez-Rattoni F. Reversible inactivation of the nucleus basalis magnocellularis induces disruption of cortical acetylcholine release and acquisition, but not retrieval, of aversive memories. Proc. Natl. Acad. Sci. USA. 1999;96(11):6478–6482. doi: 10.1073/pnas.96.11.6478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.96.11.6478</ArticleId>
            <ArticleId IdType="pmc">PMC26907</ArticleId>
            <ArticleId IdType="pubmed">10339613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunnett S.B., Everitt B.J., Robbins T.W. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 1991;14(11):494–501. doi: 10.1016/0166-2236(91)90061-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(91)90061-X</ArticleId>
            <ArticleId IdType="pubmed">1726766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasselmo M.E., Anderson B.P., Bower J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol. 1992;67(5):1230–1246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1597709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarter M., Bruno J.P. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. 1997. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-0173(96)00009-4</ArticleId>
            <ArticleId IdType="pubmed">9063585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blokland A., Honig W., Raaijmakers W.G. Effects of intra-hippocampal scopolamine injections in a repeated spatial acquisition task in the rat. Psychopharmacology (Berl.) 1992;109(3):373–376. doi: 10.1007/BF02245886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02245886</ArticleId>
            <ArticleId IdType="pubmed">1365638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winters B.D., Bussey T.J. Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat. Eur. J. Neurosci. 2005;21(8):2263–2270. doi: 10.1111/j.1460-9568.2005.04055.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2005.04055.x</ArticleId>
            <ArticleId IdType="pubmed">15869523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Power A.E., Vazdarjanova A., McGaugh J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol. Learn. Mem. 2003;80(3):178–193. doi: 10.1016/S1074-7427(03)00086-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7427(03)00086-8</ArticleId>
            <ArticleId IdType="pubmed">14521862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boccia M.M., Acosta G.B., Blake M.G., Baratti C.M. Memory consolidation and reconsolidation of an inhibitory avoidance response in mice: effects of i.c.v. injections of hemicholinium-3. 2004. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2004.01.001</ArticleId>
            <ArticleId IdType="pubmed">15026114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boccia M.M., Blake M.G., Baratti C.M., McGaugh J.L. Involvement of the basolateral amygdala in muscarinic cholinergic modulation of extinction memory consolidation. Neurobiol. Learn. Mem. 2009;91(1):93–97. doi: 10.1016/j.nlm.2008.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nlm.2008.07.012</ArticleId>
            <ArticleId IdType="pmc">PMC2673982</ArticleId>
            <ArticleId IdType="pubmed">18706510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boccia M.M., Blake M.G., Acosta G.B., Baratti C.M. Atropine, an anticholinergic drug, impairs memory retrieval of a high consolidated avoidance response in mice. Neurosci. Lett. 2003;345(2):97–100. doi: 10.1016/S0304-3940(03)00493-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3940(03)00493-2</ArticleId>
            <ArticleId IdType="pubmed">12821180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981;10(2):122–126. doi: 10.1002/ana.410100203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410100203</ArticleId>
            <ArticleId IdType="pubmed">7283399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237–1239. doi: 10.1126/science.7058341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7058341</ArticleId>
            <ArticleId IdType="pubmed">7058341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janowsky DS. R.S. Cholinomimetic and anticholinergic drugs used
to investigate an acetylcholine hypothesis of affective disorder and
stress.  Drug Dev. Res. 1984;4(17) doi: 10.1002/ddr.430040202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ddr.430040202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman M.B., Nazian S.J., Sanberg P.R., Diamond D.M., Shytle R.D. Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2001;25(3):609–620. doi: 10.1016/S0278-5846(00)00178-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0278-5846(00)00178-0</ArticleId>
            <ArticleId IdType="pubmed">11371000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matta S.G., Fu Y., Valentine J.D., Sharp B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology. 1998;23(2):103–113. doi: 10.1016/S0306-4530(97)00079-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0306-4530(97)00079-6</ArticleId>
            <ArticleId IdType="pubmed">9621392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jasper H.H., Tessier J. Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep. Science. 1971;172(3983):601–602. doi: 10.1126/science.172.3983.601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.172.3983.601</ArticleId>
            <ArticleId IdType="pubmed">4324472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baghdoyan H.A., Rodrigo-Angulo M.L., McCarley R.W., Hobson J.A. Site-specific enhancement and suppression of desynchronized sleep signs following cholinergic stimulation of three brainstem regions. Brain Res. 1984;306(1-2):39–52. doi: 10.1016/0006-8993(84)90354-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(84)90354-8</ArticleId>
            <ArticleId IdType="pubmed">6466986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donoghue J.P., Carroll K.L. Cholinergic modulation of sensory responses in rat primary somatic sensory cortex. Brain Res. 1987;408(1-2):367–371. doi: 10.1016/0006-8993(87)90407-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(87)90407-0</ArticleId>
            <ArticleId IdType="pubmed">3594226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metherate R., Cox C.L., Ashe J.H. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine. J. Neurosci. 1992;12(12):4701–4711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6575759</ArticleId>
            <ArticleId IdType="pubmed">1361197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmusson D.D., Dykes R.W. Long-term enhancement of evoked potentials in cat somatosensory cortex produced by co-activation of the basal forebrain and cutaneous receptors. Exp. Brain Res. 1988;70(2):276–286. doi: 10.1007/BF00248353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00248353</ArticleId>
            <ArticleId IdType="pubmed">3384031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillito A.M., Kemp J.A. Cholinergic modulation of the functional organization of the cat visual cortex. Brain Res. 1983;289(1-2):143–155. doi: 10.1016/0006-8993(83)90015-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(83)90015-X</ArticleId>
            <ArticleId IdType="pubmed">6661640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paez-Gonzalez P., Asrican B., Rodriguez E., Kuo C.T. Identification of distinct ChAT⁺ neurons and activity-dependent control of postnatal SVZ neurogenesis. Nat. Neurosci. 2014;17(7):934–942. doi: 10.1038/nn.3734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.3734</ArticleId>
            <ArticleId IdType="pmc">PMC4122286</ArticleId>
            <ArticleId IdType="pubmed">24880216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter L.T. Synthesis, storage and release of [14C]acetylcholine in isolated rat diaphragm muscles. J. Physiol. 1970;206(1):145–166. doi: 10.1113/jphysiol.1970.sp009003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1970.sp009003</ArticleId>
            <ArticleId IdType="pmc">PMC1348592</ArticleId>
            <ArticleId IdType="pubmed">5498453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nachmansohn D., Machado A.L. The formation of acetylcholine. A new enzyme choline acetylase. J. Neurophysiol. 1943;6:397–403.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffbauer F.W., Zaki F.G. Choline deficiency in baboon and rat compared. Arch. Pathol. 1965;79:364–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14254906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisel S.H., Da Costa K.A., Franklin P.D., Alexander E.A., Lamont J.T., Sheard N.F., Beiser A. Choline, an essential nutrient for humans. FASEB J. 1991;5(7):2093–2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2010061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benishin C.G., Carroll P.T. Acetylation of choline and homocholine by membrane-bound choline-O-acetyltransferase in mouse forebrain nerve endings. J. Neurochem. 1981;36(2):732–740. doi: 10.1111/j.1471-4159.1981.tb01649.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1981.tb01649.x</ArticleId>
            <ArticleId IdType="pubmed">7463088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rylett R.J. Synaptosomal “membrane-bound” choline acetyltransferase is most sensitive to inhibition by choline mustard. J. Neurochem. 1989;52(3):869–875. doi: 10.1111/j.1471-4159.1989.tb02535.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1989.tb02535.x</ArticleId>
            <ArticleId IdType="pubmed">2918313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misawa H., Matsuura J., Oda Y., Takahashi R., Deguchi T. Human choline acetyltransferase mRNAs with different 5'-region
produce a 69-kDa major translation product.  Brain Res. Mol. Brain
Res. 1997;44:323–333. doi: 10.1016/S0169-328X(96)00231-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0169-328X(96)00231-8</ArticleId>
            <ArticleId IdType="pubmed">9073174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oda Y., Nakanishi I., Deguchi T. A complementary DNA for human choline acetyltransferase induces two forms of enzyme with different molecular weights in cultured cells. 1992. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0169-328X(92)90237-6</ArticleId>
            <ArticleId IdType="pubmed">1337937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Resendes M.C., Dobransky T., Ferguson S.S., Rylett R.J. Nuclear localization of the 82-kDa form of human choline acetyltransferase. J. Biol. Chem. 1999;274(27):19417–19421. doi: 10.1074/jbc.274.27.19417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.27.19417</ArticleId>
            <ArticleId IdType="pubmed">10383456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill S.K., Bhattacharya M., Ferguson S.S., Rylett R.J. Identification of a novel nuclear localization signal common to 69- and 82-kDa human choline acetyltransferase. J. Biol. Chem. 2003;278(22):20217–20224. doi: 10.1074/jbc.M213153200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M213153200</ArticleId>
            <ArticleId IdType="pubmed">12637523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill S.K., Ishak M., Dobransky T., Haroutunian V., Davis K.L., Rylett R.J. 82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease. Neurobiol. Aging. 2007;28(7):1028–1040. doi: 10.1016/j.neurobiolaging.2006.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.011</ArticleId>
            <ArticleId IdType="pubmed">16797789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruce G., Hersh L.B. The phosphorylation of choline acetyltransferase. Neurochem. Res. 1989;14(7):613–620. doi: 10.1007/BF00964869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00964869</ArticleId>
            <ArticleId IdType="pubmed">2506478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt B.M., Rylett R.J. Phosphorylation of rat brain choline acetyltransferase and its relationship to enzyme activity. 1993. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb09815.x</ArticleId>
            <ArticleId IdType="pubmed">8228993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobransky T., Davis W.L., Xiao G.H., Rylett R.J. Expression, purification and characterization of recombinant human choline acetyltransferase: phosphorylation of the enzyme regulates catalytic activity. Biochem. J. 2000;349(Pt 1):141–151. doi: 10.1042/bj3490141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj3490141</ArticleId>
            <ArticleId IdType="pmc">PMC1221131</ArticleId>
            <ArticleId IdType="pubmed">10861222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collier B., Katz H.S. Acetylcholine synthesis from recaptured choline by a sympathetic ganglion. J. Physiol. 1974;238(3):639–655. doi: 10.1113/jphysiol.1974.sp010548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1974.sp010548</ArticleId>
            <ArticleId IdType="pmc">PMC1330907</ArticleId>
            <ArticleId IdType="pubmed">4850387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon J.R., Kuhar M.G. Impulse-flow regulation of high affinity choline uptake in brain cholinergic nerve terminals. Nature. 1975;255(5504):162–163. doi: 10.1038/255162a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/255162a0</ArticleId>
            <ArticleId IdType="pubmed">165430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roghani A., Feldman J., Kohan S.A., Shirzadi A., Gundersen C.B., Brecha N., Edwards R. h. Molecular cloning of a putative vesicular transporter for acetylcholine. 1994. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.91.22.10620</ArticleId>
            <ArticleId IdType="pmc">PMC45073</ArticleId>
            <ArticleId IdType="pubmed">7938002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bejanin S., Cervini R., Mallet J., Berrard S. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem. 1994;269(35):21944–21947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8071313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erickson J.D., Varoqui H., Schäfer M.K., Modi W., Diebler M.F., Weihe E., Rand J., Eiden L.E., Bonner T.I., Usdin T.B. Functional identification of a vesicular acetylcholine transporter and its expression from a “cholinergic” gene locus. J. Biol. Chem. 1994;269(35):21929–21932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8071310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfonso A., Grundahl K., McManus J.R., Asbury J.M., Rand J.B. Alternative splicing leads to two cholinergic proteins in Caenorhabditis elegans. J. Mol. Biol. 1994;241(4):627–630. doi: 10.1006/jmbi.1994.1538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/jmbi.1994.1538</ArticleId>
            <ArticleId IdType="pubmed">8057385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eiden L.E. The cholinergic gene locus. J. Neurochem. 1998;70(6):2227–2240. doi: 10.1046/j.1471-4159.1998.70062227.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.1998.70062227.x</ArticleId>
            <ArticleId IdType="pubmed">9603187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamoto T., Wang W., Salvaterra P.M. Structure and organization of the Drosophila cholinergic locus. J. Biol. Chem. 1998;273(5):2706–2713. doi: 10.1074/jbc.273.5.2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.5.2706</ArticleId>
            <ArticleId IdType="pubmed">9446576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misawa H., Ishii K., Deguchi T. Gene expression of mouse choline acetyltransferase. Alternative splicing and identification of a highly active promoter region. J. Biol. Chem. 1992;267(28):20392–20399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1400357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cervini R., Houhou L., Pradat P.F., Béjanin S., Mallet J., Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 1995;270(42):24654–24657. doi: 10.1074/jbc.270.42.24654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.270.42.24654</ArticleId>
            <ArticleId IdType="pubmed">7559575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usdin T.B., Eiden L.E., Bonner T.I., Erickson J.D. Molecular biology of the vesicular ACh transporter. Trends Neurosci. 1995;18(5):218–224. doi: 10.1016/0166-2236(95)93906-E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(95)93906-E</ArticleId>
            <ArticleId IdType="pubmed">7610492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holler T., Berse B., Cermak J.M., Diebler M.F., Blusztajn J.K. Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Neurosci. Lett. 1996;212(2):107–110. doi: 10.1016/0304-3940(96)12808-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(96)12808-1</ArticleId>
            <ArticleId IdType="pubmed">8832650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfonso A., Grundahl K., Duerr J.S., Han H.P., Rand J.B. The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science. 1993;261(5121):617–619. doi: 10.1126/science.8342028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.8342028</ArticleId>
            <ArticleId IdType="pubmed">8342028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varoqui H., Diebler M.F., Meunier F.M., Rand J.B., Usdin T.B., Bonner T.I., Eiden L.E., Erickson J.D. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans. FEBS Lett. 1994;342(1):97–102. doi: 10.1016/0014-5793(94)80592-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(94)80592-X</ArticleId>
            <ArticleId IdType="pubmed">8143858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittaker V.P. Cholinergic synaptic vesicles from the electromotor nerve terminals of Torpedo. 1987. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3296914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebois R.V., Reynolds E.E., Toll L., Howard B.D. Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry. 1980;19(6):1240–1248. doi: 10.1021/bi00547a031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi00547a031</ArticleId>
            <ArticleId IdType="pubmed">7370231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson D.C., King S.C., Parsons S.M. Pharmacological characterization of the acetylcholine transport system in purified Torpedo electric organ synaptic vesicles. Mol. Pharmacol. 1983;24(1):48–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6865925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahr B.A., Parsons S.M. Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4-phenyl[3,4-3H]-piperidino) cyclohexanol. Proc. Natl. Acad. Sci. USA. 1986;83(7):2267–2270. doi: 10.1073/pnas.83.7.2267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.7.2267</ArticleId>
            <ArticleId IdType="pmc">PMC323273</ArticleId>
            <ArticleId IdType="pubmed">3457385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varoqui H., Erickson J.D. The cytoplasmic tail of the vesicular acetylcholine transporter contains a synaptic vesicle targeting signal. J. Biol. Chem. 1998;273(15):9094–9098. doi: 10.1074/jbc.273.15.9094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.15.9094</ArticleId>
            <ArticleId IdType="pubmed">9535898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krantz D.E., Waites C., Oorschot V., Liu Y., Wilson R.I., Tan P.K., Klumperman J., Edwards R.H. A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles. J. Cell Biol. 2000;149(2):379–396. doi: 10.1083/jcb.149.2.379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.149.2.379</ArticleId>
            <ArticleId IdType="pmc">PMC2175167</ArticleId>
            <ArticleId IdType="pubmed">10769030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santos M.S., Barbosa J., Jr, Veloso G.S., Ribeiro F., Kushmerick C., Gomez M.V., Ferguson S.S., Prado V.F., Prado M.A. Trafficking of green fluorescent protein tagged-vesicular acetylcholine transporter to varicosities in a cholinergic cell line. J. Neurochem. 2001;78(5):1104–1113. doi: 10.1046/j.1471-4159.2001.00494.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.2001.00494.x</ArticleId>
            <ArticleId IdType="pubmed">11553684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira L.T., Santos M.S., Kolmakova N.G., Koenen J., Barbosa J., Jr, Gomez M.V., Guatimosim C., Zhang X., Parsons S.M., Prado V.F., Prado M.A. Structural requirements for steady-state localization of the vesicular acetylcholine transporter. J. Neurochem. 2005;94(4):957–969. doi: 10.1111/j.1471-4159.2005.03244.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2005.03244.x</ArticleId>
            <ArticleId IdType="pubmed">16092939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa J., Jr, Clarizia A.D., Gomez M.V., Romano-Silva M.A., Prado V.F., Prado M.A. Effect of protein kinase C activation on the release of [3H]acetylcholine in the presence of vesamicol. J. Neurochem. 1997;69(6):2608–2611. doi: 10.1046/j.1471-4159.1997.69062608.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.1997.69062608.x</ArticleId>
            <ArticleId IdType="pubmed">9375695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho G.W., Kim M.H., Chai Y.G., Gilmor M.L., Levey A.I., Hersh L.B. Phosphorylation of the rat vesicular acetylcholine transporter. J. Biol. Chem. 2000;275(26):19942–19948. doi: 10.1074/jbc.M902174199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M902174199</ArticleId>
            <ArticleId IdType="pubmed">10748073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prado V.F., Martins-Silva C., de Castro B.M., Lima R.F., Barros D.M., Amaral E., Ramsey A.J., Sotnikova T.D., Ramirez M.R., Kim H.G., Rossato J.I., Koenen J., Quan H., Cota V.R., Moraes M.F., Gomez M.V., Guatimosim C., Wetsel W.C., Kushmerick C., Pereira G.S., Gainetdinov R.R., Izquierdo I., Caron M.G., Prado M.A. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron. 2006;51(5):601–612. doi: 10.1016/j.neuron.2006.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2006.08.005</ArticleId>
            <ArticleId IdType="pubmed">16950158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augustinsson K.B., Nachmansohn D. Distinction between Acetylcholine-Esterase and Other Choline Ester-splitting Enzymes. 1949. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.110.2847.98</ArticleId>
            <ArticleId IdType="pubmed">17837670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall Z.W. Multiple forms of acetylcholinesterase and their distribution in endplate and non-endplate regions of rat diaphragm muscle. J. Neurobiol. 1973;4(4):343–361. doi: 10.1002/neu.480040404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/neu.480040404</ArticleId>
            <ArticleId IdType="pubmed">4724813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahan U.J., Sanes J.R., Marshall L.M. Cholinesterase is associated with the basal lamina at the neuromuscular junction. Nature. 1978;271(5641):172–174. doi: 10.1038/271172a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/271172a0</ArticleId>
            <ArticleId IdType="pubmed">622157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter P.E., Hadjiconstantinou M., Meek J.L., Neff N.H. Measurement of acetylcholine turnover rate in brain: an adjunct to a simple HPLC method for choline and acetylcholine. J. Neurochem. 1984;43(1):288–290. doi: 10.1111/j.1471-4159.1984.tb06712.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1984.tb06712.x</ArticleId>
            <ArticleId IdType="pubmed">6726255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soreq H., Seidman S.  Acetylcholinesterase--new roles for an old
actor. .  Nat. Rev. Neurosci. 2001;2:294–302. doi: 10.1038/35067589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35067589</ArticleId>
            <ArticleId IdType="pubmed">11283752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher M., Maulet Y., Camp S., Taylor P. Multiple messenger RNA species give rise to the structural diversity in acetylcholinesterase. J. Biol. Chem. 1988;263(35):18979–18987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3198606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maulet Y., Camp S., Gibney G., Rachinsky T.L., Ekström T.J., Taylor P. Single gene encodes glycophospholipid-anchored and asymmetric acetylcholinesterase forms: alternative coding exons contain inverted repeat sequences. Neuron. 1990;4(2):289–301. doi: 10.1016/0896-6273(90)90103-M.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0896-6273(90)90103-M</ArticleId>
            <ArticleId IdType="pubmed">2306366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidman S., Sternfeld M., Ben Aziz-Aloya R., Timberg R., Kaufer-Nachum D., Soreq H. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3′-terminal exons. Mol. Cell. Biol. 1995;15(6):2993–3002. doi: 10.1128/MCB.15.6.2993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.15.6.2993</ArticleId>
            <ArticleId IdType="pmc">PMC230530</ArticleId>
            <ArticleId IdType="pubmed">7760797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts W.L., Kim B.H., Rosenberry T.L. Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc. Natl. Acad. Sci. USA. 1987;84(22):7817–7821. doi: 10.1073/pnas.84.22.7817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.84.22.7817</ArticleId>
            <ArticleId IdType="pmc">PMC299404</ArticleId>
            <ArticleId IdType="pubmed">3479767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Camp S., Rachinsky T.L., Getman D., Taylor P. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J. Biol. Chem. 1991;266(34):23083–23090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1744105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa L.G. Current issues in organophosphate toxicology. 2006. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2005.10.008</ArticleId>
            <ArticleId IdType="pubmed">16337171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson I.B. Molecular complementarity and antidotes for alkylphosphate poisoning. Fed. Proc. 1959;18(2, Part 1):752–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13672268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Schaepdryver A., Marion C. [Succinylcholine in anesthesiology]. Acta Anaesthesiol. 1952;3(1):105–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13007297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo J.C., DeBEER E.J. The neuromuscular blocking action of succinylcholine (diacetylcholine). J. Pharmacol. Exp. Ther. 1950;99(4:1):458–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15437324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns A., Russell E., Page S. New drugs for Alzheimer’s disease. Br. J. Psychiatry. 1999;174:476–479. doi: 10.1192/bjp.174.6.476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.174.6.476</ArticleId>
            <ArticleId IdType="pubmed">10616624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis K.L., Mohs R.C., Tinklenberg J.R. Physostigmine: improvement of long-term memory processes in normal humans. 1978. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.351807</ArticleId>
            <ArticleId IdType="pubmed">351807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birks R.I., MacIntosh F.C., Birks R.I., MacIntosh F.C. Acetylcholine metabolism of a sympathetic ganglion. Can. J. Biochem. Physiol. 1961;39:787–827. doi: 10.1139/o61-081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/o61-081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tucek S. Regulation of acetylcholine synthesis in the brain. J. Neurochem. 1985;44(1):11–24. doi: 10.1111/j.1471-4159.1985.tb07106.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1985.tb07106.x</ArticleId>
            <ArticleId IdType="pubmed">3880580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vickroy T.W., Roeske W.R., Gehlert D.R., Wamsley J.K., Yamamura H.I. Quantitative light microscopic autoradiography of [3H]hemicholinium-3 binding sites in the rat central nervous system: a novel biochemical marker for mapping the distribution of cholinergic nerve terminals. Brain Res. 1985;329(1-2):368–373. doi: 10.1016/0006-8993(85)90553-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(85)90553-0</ArticleId>
            <ArticleId IdType="pubmed">3978459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misawa H., Nakata K., Matsuura J., Nagao M., Okuda T., Haga T., Matsumura G., Nishimura Y., Haga T. Distribution of the high-affinity choline transporter in the central nervous system of the rat. Neuroscience. 2001;105(1):87–98. doi: 10.1016/S0306-4522(01)00147-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0306-4522(01)00147-6</ArticleId>
            <ArticleId IdType="pubmed">11483303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi Y., Okuda T., Fujioka Y., Matsumura G., Nishimura Y., Haga T. Distribution of the high-affinity choline transporter in the human and macaque monkey spinal cord. Neurosci. Lett. 2002;317(1):25–28. doi: 10.1016/S0304-3940(01)02413-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3940(01)02413-2</ArticleId>
            <ArticleId IdType="pubmed">11750988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haga T. Synthesis and release of ( 14 C)acetylcholine in synaptosomes. J. Neurochem. 1971;18(6):781–798. doi: 10.1111/j.1471-4159.1971.tb12008.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1971.tb12008.x</ArticleId>
            <ArticleId IdType="pubmed">5105924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhar M.J., Murrin L.C. Sodium-dependent, high affinity choline uptake. J. Neurochem. 1978;30(1):15–21. doi: 10.1111/j.1471-4159.1978.tb07029.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1978.tb07029.x</ArticleId>
            <ArticleId IdType="pubmed">340615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson S.M., Bazalakova M., Savchenko V., Tapia J.C., Wright J., Blakely R.D. Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Proc. Natl. Acad. Sci. USA. 2004;101(23):8762–8767. doi: 10.1073/pnas.0401667101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0401667101</ArticleId>
            <ArticleId IdType="pmc">PMC423269</ArticleId>
            <ArticleId IdType="pubmed">15173594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson S.M., Savchenko V., Apparsundaram S., Zwick M., Wright J., Heilman C.J., Yi H., Levey A.I., Blakely R.D. Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J. Neurosci. 2003;23(30):9697–9709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6740902</ArticleId>
            <ArticleId IdType="pubmed">14585997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro F.M., Alves-Silva J., Volknandt W., Martins-Silva C., Mahmud H., Wilhelm A., Gomez M.V., Rylett R.J., Ferguson S.S., Prado V.F., Prado M.A. The hemicholinium-3 sensitive high affinity choline transporter is internalized by clathrin-mediated endocytosis and is present in endosomes and synaptic vesicles. J. Neurochem. 2003;87(1):136–146. doi: 10.1046/j.1471-4159.2003.01974.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.2003.01974.x</ArticleId>
            <ArticleId IdType="pubmed">12969261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakata K., Okuda T., Misawa H. Ultrastructural localization of high-affinity choline transporter in the rat neuromuscular junction: enrichment on synaptic vesicles. Synapse. 2004;53(1):53–56. doi: 10.1002/syn.20029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/syn.20029</ArticleId>
            <ArticleId IdType="pubmed">15150741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro F.M., Black S.A., Cregan S.P., Prado V.F., Prado M.A., Rylett R.J., Ferguson S.S. Constitutive high-affinity choline transporter endocytosis is determined by a carboxyl-terminal tail dileucine motif. J. Neurochem. 2005;94(1):86–96. doi: 10.1111/j.1471-4159.2005.03171.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2005.03171.x</ArticleId>
            <ArticleId IdType="pubmed">15953352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro F.M., Pinthong M., Black S.A., Gordon A.C., Prado V.F., Prado M.A., Rylett R.J., Ferguson S.S. Regulated recycling and plasma membrane recruitment of the high-affinity choline transporter. Eur. J. Neurosci. 2007;26(12):3437–3448. doi: 10.1111/j.1460-9568.2007.05967.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2007.05967.x</ArticleId>
            <ArticleId IdType="pubmed">18088276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Regan S., Collier B. Effect of increasing choline, in vivo and in vitro, on the synthesis of acetylcholine in a sympathetic ganglion. J. Neurochem. 1981;36(2):420–430. doi: 10.1111/j.1471-4159.1981.tb01610.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1981.tb01610.x</ArticleId>
            <ArticleId IdType="pubmed">7463070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saltarelli M.D., Lowenstein P.R., Coyle J.T. Rapid in vitro modulation of [3H]hemicholinium-3 binding sites in rat striatal slices. Eur. J. Pharmacol. 1987;135(1):35–40. doi: 10.1016/0014-2999(87)90754-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-2999(87)90754-0</ArticleId>
            <ArticleId IdType="pubmed">3569424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apparsundaram S., Martinez V., Parikh V., Kozak R., Sarter M. Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. J. Neurosci. 2005;25(15):3851–3856. doi: 10.1523/JNEUROSCI.0205-05.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0205-05.2005</ArticleId>
            <ArticleId IdType="pmc">PMC6724940</ArticleId>
            <ArticleId IdType="pubmed">15829637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levey A.I., Armstrong D.M., Atweh S.F., Terry R.D., Wainer B.H. Monoclonal antibodies to choline acetyltransferase: production, specificity, and immunohistochemistry. J. Neurosci. 1983;3(1):1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6564589</ArticleId>
            <ArticleId IdType="pubmed">6822847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolf N.J., Butcher L.L. Cholinergic neurons in the caudate-putamen complex proper are intrinsically organized: a combined Evans blue and acetylcholinesterase analysis. Brain Res. Bull. 1981;7(5):487–507. doi: 10.1016/0361-9230(81)90004-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0361-9230(81)90004-6</ArticleId>
            <ArticleId IdType="pubmed">7317794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolam J.P., Wainer B.H., Smith A.D. Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience. 1984;12(3):711–718. doi: 10.1016/0306-4522(84)90165-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(84)90165-9</ArticleId>
            <ArticleId IdType="pubmed">6382048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 1983;214(2):170–197. doi: 10.1002/cne.902140206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.902140206</ArticleId>
            <ArticleId IdType="pubmed">6841683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesulam M.M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience. 1983;10(4):1185–1201. doi: 10.1016/0306-4522(83)90108-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(83)90108-2</ArticleId>
            <ArticleId IdType="pubmed">6320048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 2004;145:67–78. doi: 10.1016/S0079-6123(03)45004-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0079-6123(03)45004-8</ArticleId>
            <ArticleId IdType="pubmed">14650907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson R.T., DeLong M.R. A reappraisal of the functions of the nucleus basalis of Meynert. Trends Neurosci. 1988;11(6):264–267. doi: 10.1016/0166-2236(88)90107-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(88)90107-5</ArticleId>
            <ArticleId IdType="pubmed">2465623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Everitt B.J., Robbins T.W. Central cholinergic systems and cognition. Annu. Rev. Psychol. 1997;48:649–684. doi: 10.1146/annurev.psych.48.1.649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.psych.48.1.649</ArticleId>
            <ArticleId IdType="pubmed">9046571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberger N.M. The nucleus basalis and memory codes: auditory cortical plasticity and the induction of specific, associative behavioral memory. Neurobiol. Learn. Mem. 2003;80(3):268–284. doi: 10.1016/S1074-7427(03)00072-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7427(03)00072-8</ArticleId>
            <ArticleId IdType="pubmed">14521869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones B.E. Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. 2004. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0079-6123(03)45011-5</ArticleId>
            <ArticleId IdType="pubmed">14650914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rye D.B., Saper C.B., Lee H.J., Wainer B.H. Pedunculopontine tegmental nucleus of the rat: cytoarchitecture, cytochemistry, and some extrapyramidal connections of the mesopontine tegmentum. J. Comp. Neurol. 1987;259(4):483–528. doi: 10.1002/cne.902590403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.902590403</ArticleId>
            <ArticleId IdType="pubmed">2885347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobson J.A., McCarley R.W., Wyzinski P.W. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. 1975. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1094539</ArticleId>
            <ArticleId IdType="pubmed">1094539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyoshima C., Unwin N. Three-dimensional structure of the acetylcholine receptor by cryoelectron microscopy and helical image reconstruction. J. Cell Biol. 1990;111(6 Pt 1):2623–2635. doi: 10.1083/jcb.111.6.2623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.111.6.2623</ArticleId>
            <ArticleId IdType="pmc">PMC2116367</ArticleId>
            <ArticleId IdType="pubmed">2277076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brisson A., Unwin P.N. Quaternary structure of the acetylcholine receptor. Nature. 1985;315(6019):474–477. doi: 10.1038/315474a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/315474a0</ArticleId>
            <ArticleId IdType="pubmed">4000275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brisson A., Unwin P.N. Tubular crystals of acetylcholine receptor. 1984. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.99.4.1202</ArticleId>
            <ArticleId IdType="pmc">PMC2113304</ArticleId>
            <ArticleId IdType="pubmed">6480689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper E., Couturier S., Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature. 1991;350(6315):235–238. doi: 10.1038/350235a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/350235a0</ArticleId>
            <ArticleId IdType="pubmed">2005979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nai Q., McIntosh J.M., Margiotta J.F. Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function. Mol. Pharmacol. 2003;63(2):311–324. doi: 10.1124/mol.63.2.311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.63.2.311</ArticleId>
            <ArticleId IdType="pubmed">12527802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Séguéla P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993;13(2):596–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6576637</ArticleId>
            <ArticleId IdType="pubmed">7678857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J. Neurosci. 1997;17(15):5747–5759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6573211</ArticleId>
            <ArticleId IdType="pubmed">9221773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 1996;16(6):1077–1085. doi: 10.1016/S0896-6273(00)80134-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(00)80134-8</ArticleId>
            <ArticleId IdType="pubmed">8663984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whyte J., Harrison R., Lunt G.G., Wonnacott S. Subcellular fractionation and distribution of cholinergic binding sites in fetal human brain. Neurochem. Res. 1986;11(7):1011–1023. doi: 10.1007/BF00965590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00965590</ArticleId>
            <ArticleId IdType="pubmed">3748272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radcliffe K.A., Dani J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J. Neurosci. 1998;18(18):7075–7083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793238</ArticleId>
            <ArticleId IdType="pubmed">9736631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 1996;383(6602):713–716. doi: 10.1038/383713a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/383713a0</ArticleId>
            <ArticleId IdType="pubmed">8878480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radcliffe K.A., Fisher J.L., Gray R., Dani J.A. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann. N. Y. Acad. Sci. 1999;868:591–610. doi: 10.1111/j.1749-6632.1999.tb11332.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1999.tb11332.x</ArticleId>
            <ArticleId IdType="pubmed">10414340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269(5231):1692–1696. doi: 10.1126/science.7569895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7569895</ArticleId>
            <ArticleId IdType="pubmed">7569895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkie G.I., Hutson P., Sullivan J.P., Wonnacott S. Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. Neurochem. Res. 1996;21(9):1141–1148. doi: 10.1007/BF02532425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02532425</ArticleId>
            <ArticleId IdType="pubmed">8897478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke P.B., Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br. J. Pharmacol. 1996;117(4):595–606. doi: 10.1111/j.1476-5381.1996.tb15232.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.1996.tb15232.x</ArticleId>
            <ArticleId IdType="pmc">PMC1909326</ArticleId>
            <ArticleId IdType="pubmed">8646402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nisell M., Nomikos G.G., Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994;16(1):36–44. doi: 10.1002/syn.890160105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/syn.890160105</ArticleId>
            <ArticleId IdType="pubmed">8134899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X., Criswell H.E., Breese G.R. Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-containing neurons. J. Pharmacol. Exp. Ther. 1996;276(2):482–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8632313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wessler I. Acetylcholine at motor nerves: storage, release, and presynaptic modulation by autoreceptors and adrenoceptors. Int. Rev. Neurobiol. 1992;34:283–384. doi: 10.1016/S0074-7742(08)60100-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0074-7742(08)60100-2</ArticleId>
            <ArticleId IdType="pubmed">1587718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20(2):92–98. doi: 10.1016/S0166-2236(96)10073-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-2236(96)10073-4</ArticleId>
            <ArticleId IdType="pubmed">9023878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.S., Levin E.D. Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. Brain Res. 1996;725(2):231–240. doi: 10.1016/0006-8993(96)00213-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(96)00213-2</ArticleId>
            <ArticleId IdType="pubmed">8836529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl.) 1998;138(3-4):217–230. doi: 10.1007/s002130050667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002130050667</ArticleId>
            <ArticleId IdType="pubmed">9725745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin E.D., Torry D. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology (Berl.) 1996;123(1):88–97. doi: 10.1007/BF02246285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02246285</ArticleId>
            <ArticleId IdType="pubmed">8741959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felix R., Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience. 1997;81(4):1009–1017. doi: 10.1016/S0306-4522(97)00224-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0306-4522(97)00224-8</ArticleId>
            <ArticleId IdType="pubmed">9330363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dajas-Bailador F.A., Lima P.A., Wonnacott S. The alpha7
nicotinic acetylcholine receptor subtype mediates nicotine
protection against NMDA excitotoxicity in primary hippocampal
cultures through a Ca(2+) dependent mechanism. .  Neuropharmacology . 2000;39 :2799–2807. doi: 10.1016/S0028-3908(00)00127-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0028-3908(00)00127-1</ArticleId>
            <ArticleId IdType="pubmed">11044750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Neill M.J., Murray T.K., Lakics V., Visanji N.P., Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 2002;1(4):399–411. doi: 10.2174/1568007023339166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568007023339166</ArticleId>
            <ArticleId IdType="pubmed">12769612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu Y.N., Edwards S.C., Wecker L. Nicotine enhances the cyclic AMP-dependent protein kinase-mediated phosphorylation of alpha4 subunits of neuronal nicotinic receptors. 1997. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9375675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho C.H., Song W., Leitzell K., Teo E., Meleth A.D., Quick M.W., Lester R.A. Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J. Neurosci. 2005;25(14):3712–3723. doi: 10.1523/JNEUROSCI.5389-03.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5389-03.2005</ArticleId>
            <ArticleId IdType="pmc">PMC6725387</ArticleId>
            <ArticleId IdType="pubmed">15814802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swope S.L., Moss S.J., Raymond L.A., Huganir R.L. Regulation of ligand-gated ion channels by protein phosphorylation. Adv. Second Messenger Phosphoprotein Res. 1999;33:49–78. doi: 10.1016/S1040-7952(99)80005-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1040-7952(99)80005-6</ArticleId>
            <ArticleId IdType="pubmed">10218114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charpantier E., Wiesner A., Huh K.H., Ogier R., Hoda J.C., Allaman G., Raggenbass M., Feuerbach D., Bertrand D., Fuhrer C. Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J. Neurosci. 2005;25(43):9836–9849. doi: 10.1523/JNEUROSCI.3497-05.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3497-05.2005</ArticleId>
            <ArticleId IdType="pmc">PMC6725579</ArticleId>
            <ArticleId IdType="pubmed">16251431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulle C., Lena C., Changeux J.P. Potentiation of nicotinic receptor response by external calcium in rat central neurons. 1992. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0896-6273(92)90208-U</ArticleId>
            <ArticleId IdType="pubmed">1586487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glushakov A.V., Glushakova H.Y., Skok V.I. Modulation of nicotinic acetylcholine receptor activity in submucous neurons by intracellular messengers. J. Auton. Nerv. Syst. 1999;75(1):16–22. doi: 10.1016/S0165-1838(98)00165-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-1838(98)00165-9</ArticleId>
            <ArticleId IdType="pubmed">9935265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luetje C.W., Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci. 1991;11(3):837–845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6575344</ArticleId>
            <ArticleId IdType="pubmed">1705971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997;280(1):346–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8996215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mogg A.J., Whiteaker P., McIntosh J.M., Marks M., Collins A.C., Wonnacott S. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J. Pharmacol. Exp. Ther. 2002;302(1):197–204. doi: 10.1124/jpet.302.1.197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.302.1.197</ArticleId>
            <ArticleId IdType="pubmed">12065717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nathanson N.M. A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away. 2000. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.97.12.6245</ArticleId>
            <ArticleId IdType="pmc">PMC33994</ArticleId>
            <ArticleId IdType="pubmed">10841527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237(4814):527–532. doi: 10.1126/science.3037705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.3037705</ArticleId>
            <ArticleId IdType="pubmed">3037705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubo T., Maeda A., Sugimoto K., Akiba I., Mikami A., Takahashi H., Haga T., Haga K., Ichiyama A., Kangawa K., et al.  Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett. 1986;209(2):367–372. doi: 10.1016/0014-5793(86)81144-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(86)81144-9</ArticleId>
            <ArticleId IdType="pubmed">3792556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caulfield M.P., Birdsall N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998;50(2):279–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9647869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammer R., Berrie C.P., Birdsall N.J., Burgen A.S., Hulme E.C. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980;283(5742):90–92. doi: 10.1038/283090a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/283090a0</ArticleId>
            <ArticleId IdType="pubmed">7350532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehlert F.J., Delen F.M., Yun S.H., Tran P. Differential coupling of subtypes of the muscarinic receptor to signaling mechanisms in brain and peripheral tissues. Adv. Exp. Med. Biol. 1991;287:301–312. doi: 10.1007/978-1-4684-5907-4_25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4684-5907-4_25</ArticleId>
            <ArticleId IdType="pubmed">1759614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egan T.M., North R.A. Acetylcholine hyperpolarizes central neurones by acting on an M2 muscarinic receptor. Nature. 1986;319(6052):405–407. doi: 10.1038/319405a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/319405a0</ArticleId>
            <ArticleId IdType="pubmed">2418362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J. 1995;9(8):619–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7768353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krnjević K., Pumain R., Renaud L. The mechanism of excitation by acetylcholine in the cerebral cortex. J. Physiol. 1971;215(1):247–268. doi: 10.1113/jphysiol.1971.sp009467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1971.sp009467</ArticleId>
            <ArticleId IdType="pmc">PMC1331876</ArticleId>
            <ArticleId IdType="pubmed">5579661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown D.A., Selyanko A.A. Membrane currents underlying the cholinergic slow excitatory post-synaptic potential in the rat sympathetic ganglion. J. Physiol. 1985;365:365–387. doi: 10.1113/jphysiol.1985.sp015777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1985.sp015777</ArticleId>
            <ArticleId IdType="pmc">PMC1193007</ArticleId>
            <ArticleId IdType="pubmed">2411921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo Y., Ogura A., Iijima T. Stimulation of muscarinic receptor in hippocampal neuron induces characteristic increase in cytosolic free Ca2+ concentration. Neurosci. Lett. 1988;85(3):345–350. doi: 10.1016/0304-3940(88)90590-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(88)90590-3</ArticleId>
            <ArticleId IdType="pubmed">2896321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991;11(10):3218–3226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6575445</ArticleId>
            <ArticleId IdType="pubmed">1941081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mrzljak L., Levey A.I., Goldman-Rakic P.S. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. 1993. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.90.11.5194</ArticleId>
            <ArticleId IdType="pmc">PMC46682</ArticleId>
            <ArticleId IdType="pubmed">8389473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porter A.C., Bymaster F.P., DeLapp N.W., Yamada M., Wess J., Hamilton S.E., Nathanson N.M., Felder C.C. M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res. 2002;944(1-2):82–89. doi: 10.1016/S0006-8993(02)02721-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-8993(02)02721-X</ArticleId>
            <ArticleId IdType="pubmed">12106668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douglas C.L., Baghdoyan H.A., Lydic R. M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL/6J mouse. J. Pharmacol. Exp. Ther. 2001;299(3):960–966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11714883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segal M. Presynaptic cholinergic inhibition in hippocampal cultures. 1989. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/syn.890040406</ArticleId>
            <ArticleId IdType="pubmed">2574917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Zee E.A., Luiten P.G. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. 1999. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0301-0082(98)00092-6</ArticleId>
            <ArticleId IdType="pubmed">10380240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halliwell J.V., Adams P.R. Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res. 1982;250(1):71–92. doi: 10.1016/0006-8993(82)90954-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(82)90954-4</ArticleId>
            <ArticleId IdType="pubmed">6128061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima Y., Nakajima S., Leonard R.J., Yamaguchi K. Acetylcholine raises excitability by inhibiting the fast transient potassium current in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA. 1986;83(9):3022–3026. doi: 10.1073/pnas.83.9.3022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.9.3022</ArticleId>
            <ArticleId IdType="pmc">PMC323439</ArticleId>
            <ArticleId IdType="pubmed">3010326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madison D.V., Lancaster B., Nicoll R.A. Voltage clamp analysis of cholinergic action in the hippocampus. J. Neurosci. 1987;7(3):733–741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6569053</ArticleId>
            <ArticleId IdType="pubmed">3559710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hounsgaard J. Presynaptic inhibitory action of acetylcholine in area CA1 of the hippocampus. Exp. Neurol. 1978;62(3):787–797. doi: 10.1016/0014-4886(78)90284-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-4886(78)90284-4</ArticleId>
            <ArticleId IdType="pubmed">750222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segal M. Rat hippocampal neurons in culture: responses to electrical and chemical stimuli. J. Neurophysiol. 1983;50(6):1249–1264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6663325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markram H., Segal M. The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. J. Physiol. 1992;447:513–533. doi: 10.1113/jphysiol.1992.sp019015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1992.sp019015</ArticleId>
            <ArticleId IdType="pmc">PMC1176049</ArticleId>
            <ArticleId IdType="pubmed">1593457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCormick D.A., Prince D.A. Mechanisms of action of acetylcholine in the guinea-pig cerebral cortex in vitro. J. Physiol. 1986;375:169–194. doi: 10.1113/jphysiol.1986.sp016112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1986.sp016112</ArticleId>
            <ArticleId IdType="pmc">PMC1182754</ArticleId>
            <ArticleId IdType="pubmed">2879035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovira C., Ben-Ari Y., Cherubini E., Krnjevic K., Ropert N. Pharmacology of the dendritic action of acetylcholine and further observations on the somatic disinhibition in the rat hippocampus in situ. Neuroscience. 1983;8(1):97–106. doi: 10.1016/0306-4522(83)90028-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(83)90028-3</ArticleId>
            <ArticleId IdType="pubmed">6300730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gähwiler B.H., Brown D.A. Muscarine affects calcium-currents in rat hippocampal pyramidal cells in vitro. Neurosci. Lett. 1987;76(3):301–306. doi: 10.1016/0304-3940(87)90419-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(87)90419-8</ArticleId>
            <ArticleId IdType="pubmed">3587761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adem A., Karlsson E. Muscarinic receptor subtype selective toxins. Life Sci. 1997;60(13-14):1069–1076. doi: 10.1016/S0024-3205(97)00049-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0024-3205(97)00049-0</ArticleId>
            <ArticleId IdType="pubmed">9121349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer’s disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. 1982;57(2-3):407–417. doi: 10.1016/0022-510X(82)90045-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(82)90045-4</ArticleId>
            <ArticleId IdType="pubmed">7161627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muir J.L. Acetylcholine, aging, and Alzheimer’s disease. Pharmacol. Biochem. Behav. 1997;56(4):687–696. doi: 10.1016/S0091-3057(96)00431-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0091-3057(96)00431-5</ArticleId>
            <ArticleId IdType="pubmed">9130295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000;163(2):495–529. doi: 10.1006/exnr.2000.7397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/exnr.2000.7397</ArticleId>
            <ArticleId IdType="pubmed">10833325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muir J.L., Dunnett S.B., Robbins T.W., Everitt B.J. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. 1992. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00229886</ArticleId>
            <ArticleId IdType="pubmed">1644125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogers J.L., Kesner R.P. Cholinergic modulation of the hippocampus during encoding and retrieval of tone/shock-induced fear conditioning. Learn. Mem. 2004;11(1):102–107. doi: 10.1101/lm.64604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/lm.64604</ArticleId>
            <ArticleId IdType="pmc">PMC321320</ArticleId>
            <ArticleId IdType="pubmed">14747523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg P.B., Nowrangi M.A., Lyketsos C.G. Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits? Mol. Aspects Med. 2015;43-44:25–37. doi: 10.1016/j.mam.2015.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2015.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC4600424</ArticleId>
            <ArticleId IdType="pubmed">26049034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martorana A., Koch G. “Is dopamine involved in Alzheimer’s disease?”. Front. Aging Neurosci. 2014;6:252. doi: 10.3389/fnagi.2014.00252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2014.00252</ArticleId>
            <ArticleId IdType="pmc">PMC4174765</ArticleId>
            <ArticleId IdType="pubmed">25309431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon J., Dencker D., Wörtwein G., Woldbye D.P., Cui Y., Davis A.A., Levey A.I., Schütz G., Sager T.N., Mørk A., Li C., Deng C.X., Fink-Jensen A., Wess J. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J. Neurosci. 2010;30(6):2396–2405. doi: 10.1523/JNEUROSCI.3843-09.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3843-09.2010</ArticleId>
            <ArticleId IdType="pmc">PMC2824442</ArticleId>
            <ArticleId IdType="pubmed">20147565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesulam M.M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J. Comp. Neurol. 2013;521(18):4124–4144. doi: 10.1002/cne.23415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.23415</ArticleId>
            <ArticleId IdType="pmc">PMC4175400</ArticleId>
            <ArticleId IdType="pubmed">23852922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarter M., Lustig C., Howe W.M., Gritton H., Berry A.S. Deterministic functions of cortical acetylcholine. Eur. J. Neurosci. 2014;39(11):1912–1920. doi: 10.1111/ejn.12515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.12515</ArticleId>
            <ArticleId IdType="pmc">PMC4371531</ArticleId>
            <ArticleId IdType="pubmed">24593677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nauta W.J., Smith G.P., Faull R.L., Domesick V.B. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience. 1978;3(4-5):385–401. doi: 10.1016/0306-4522(78)90041-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(78)90041-6</ArticleId>
            <ArticleId IdType="pubmed">683502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s Disease. Acta Neuropathol. 1983;61(2):101–108. doi: 10.1007/BF00697388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00697388</ArticleId>
            <ArticleId IdType="pubmed">6637393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubois B., Ruberg M., Javoy-Agid F., Ploska A., Agid Y. A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res. 1983;288(1-2):213–218. doi: 10.1016/0006-8993(83)90096-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(83)90096-3</ArticleId>
            <ArticleId IdType="pubmed">6661617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yates C.M., Simpson J., Maloney A.F., Gordon A., Reid A.H. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet. 1980;2(8201):979. doi: 10.1016/S0140-6736(80)92137-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(80)92137-6</ArticleId>
            <ArticleId IdType="pubmed">6107618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barron S.A., Mazliah J., Bental E. Sympathetic cholinergic dysfunction in amyotrophic lateral sclerosis. 1987. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.1987.tb07890.x</ArticleId>
            <ArticleId IdType="pubmed">3577669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato T. Choline acetyltransferase activities in single spinal motor neurons from patients with amyotrophic lateral sclerosis. J. Neurochem. 1989;52(2):636–640. doi: 10.1111/j.1471-4159.1989.tb09167.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.1989.tb09167.x</ArticleId>
            <ArticleId IdType="pubmed">2911033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruberg M., Javoy-Agid F., Hirsch E., Scatton B., LHeureux R., Hauw J.J., Duyckaerts C., Gray F., Morel-Maroger A., Rascol A., et al.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann. Neurol. 1985;18(5):523–529. doi: 10.1002/ana.410180503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410180503</ArticleId>
            <ArticleId IdType="pubmed">3000280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagliavini F., Pilleri G., Bouras C., Constantinidis J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci. Lett. 1984;44(1):37–42. doi: 10.1016/0304-3940(84)90217-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(84)90217-9</ArticleId>
            <ArticleId IdType="pubmed">6717850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kish S.J., el-Awar M., Schut L., Leach L., Oscar-Berman M., Freedman M. Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer’s dementia. Ann. Neurol. 1988;24(2):200–206. doi: 10.1002/ana.410240205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410240205</ArticleId>
            <ArticleId IdType="pubmed">3178175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Jr, Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington’s disease. Brain Res. 1987;411(1):162–166. doi: 10.1016/0006-8993(87)90694-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(87)90694-9</ArticleId>
            <ArticleId IdType="pubmed">2955849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aquilonius S.M., Eckernås S.A., Sundwall A. Regional distribution of choline acetyltransferase in the human brain: changes in Huntington’s chorea. J. Neurol. Neurosurg. Psychiatry. 1975;38(7):669–677. doi: 10.1136/jnnp.38.7.669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.38.7.669</ArticleId>
            <ArticleId IdType="pmc">PMC1083246</ArticleId>
            <ArticleId IdType="pubmed">125784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. 1907;64:146–148.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M., Alzheimer’s Disease International  Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. doi: 10.1016/S0140-6736(05)67889-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67889-0</ArticleId>
            <ArticleId IdType="pmc">PMC2850264</ArticleId>
            <ArticleId IdType="pubmed">16360788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125–132. doi: 10.1159/000109998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000109998</ArticleId>
            <ArticleId IdType="pmc">PMC2705925</ArticleId>
            <ArticleId IdType="pubmed">17975326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., Scheltens P., Tariska P., Winblad B., EFNS  Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 2007;14(1):e1–e26. doi: 10.1111/j.1468-1331.2006.01605.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2006.01605.x</ArticleId>
            <ArticleId IdType="pubmed">17222085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu C., Kivipelto M., von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 2009;11(2):111–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3181909</ArticleId>
            <ArticleId IdType="pubmed">19585947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De-Paula V.J., Radanovic M., Diniz B.S., Forlenza O.V. Alzheimer’s disease. Subcell. Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-94-007-5416-4_14</ArticleId>
            <ArticleId IdType="pubmed">23225010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong R.A. Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression. 2014. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/623487</ArticleId>
            <ArticleId IdType="pmc">PMC3919116</ArticleId>
            <ArticleId IdType="pubmed">24579083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garin D., Virgone-Carlotta A., Gözel B., Oukhatar F., Perret P., Marti-Battle D., Touret M., Millet P., Dubois-Dauphin M., Meyronet D., Streichenberger N., Laferla F.M., Demeunynck M., Chierici S., Sallanon M.M., Ghezzi C. COB231 targets amyloid plaques in post-mortem human brain tissue and in an Alzheimer mouse model. J. Neurochem. 2014;132(5):609–618. [Epub a head of Print].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25258048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118(1):5–36. doi: 10.1007/s00401-009-0532-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-009-0532-1</ArticleId>
            <ArticleId IdType="pubmed">19381658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taipa R., Pinho J., Melo-Pires M. Clinico-pathological correlations of the most common neurodegenerative dementias. Front. Neurol. 2012;3:68. doi: 10.3389/fneur.2012.00068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2012.00068</ArticleId>
            <ArticleId IdType="pmc">PMC3340570</ArticleId>
            <ArticleId IdType="pubmed">22557993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glenner G.G., Wong C.W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120(3):885–890. doi: 10.1016/S0006-291X(84)80190-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-291X(84)80190-4</ArticleId>
            <ArticleId IdType="pubmed">6375662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733–736. doi: 10.1038/325733a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/325733a0</ArticleId>
            <ArticleId IdType="pubmed">2881207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esch F.S., Keim P.S., Beattie E.C., Blacher R.W., Culwell A.R., Oltersdorf T., McClure D., Ward P.J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248(4959):1122–1124. doi: 10.1126/science.2111583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2111583</ArticleId>
            <ArticleId IdType="pubmed">2111583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30(4):572–580. doi: 10.1002/ana.410300410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410300410</ArticleId>
            <ArticleId IdType="pubmed">1789684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terry R.D. Alzheimer’s disease and the aging brain. J. Geriatr. Psychiatry Neurol. 2006;19(3):125–128. doi: 10.1177/0891988706291079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0891988706291079</ArticleId>
            <ArticleId IdType="pubmed">16880353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1986;83(11):4044–4048. doi: 10.1073/pnas.83.11.4044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.11.4044</ArticleId>
            <ArticleId IdType="pmc">PMC323662</ArticleId>
            <ArticleId IdType="pubmed">2424016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood J.G., Mirra S.S., Pollock N.J., Binder L.I.  Neurofibrillary
tangles of Alzheimer disease share antigenic determinants with the
axonal microtubule-associated protein tau (tau). .  Proc. Natl. Acad.
Sci. U.S.A, 1986;83:4040–4043. doi: 10.1073/pnas.83.11.4040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.11.4040</ArticleId>
            <ArticleId IdType="pmc">PMC323661</ArticleId>
            <ArticleId IdType="pubmed">2424015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg L., McKeel D.W., Jr, Miller J.P., Baty J., Morris J.C. Neuropathological indexes of Alzheimer's disease in  demented and nondemented persons aged 80 years and older. 1993. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1993.00540040011008</ArticleId>
            <ArticleId IdType="pubmed">8460956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 1999;19(7):2706–2716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6786057</ArticleId>
            <ArticleId IdType="pubmed">10087083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell K.F., Ducatenzeiler A., Ribeiro-da-Silva A., Duff K., Bennett D.A., Cuello A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging. 2006;27(11):1644–1657. doi: 10.1016/j.neurobiolaging.2005.09.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.034</ArticleId>
            <ArticleId IdType="pubmed">16271419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selkoe D.J. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789–791. doi: 10.1126/science.1074069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1074069</ArticleId>
            <ArticleId IdType="pubmed">12399581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sze C.I., Troncoso J.C., Kawas C., Mouton P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997;56(8):933–944. doi: 10.1097/00005072-199708000-00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-199708000-00011</ArticleId>
            <ArticleId IdType="pubmed">9258263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Counts S.E., Nadeem M., Lad S.P., Wuu J., Mufson E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol. 2006;65(6):592–601. doi: 10.1097/00005072-200606000-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-200606000-00007</ArticleId>
            <ArticleId IdType="pubmed">16783169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. USA. 1999;96(6):3228–3233. doi: 10.1073/pnas.96.6.3228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.96.6.3228</ArticleId>
            <ArticleId IdType="pmc">PMC15924</ArticleId>
            <ArticleId IdType="pubmed">10077666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzjohn S.M., Morton R.A., Kuenzi F., Rosahl T.W., Shearman M., Lewis H., Smith D., Reynolds D.S., Davies C.H., Collingridge G.L., Seabrook G.R. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 2001;21(13):4691–4698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6762352</ArticleId>
            <ArticleId IdType="pubmed">11425896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm (Vienna) 2006;113(11):1625–1644. doi: 10.1007/s00702-006-0579-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-006-0579-2</ArticleId>
            <ArticleId IdType="pubmed">17039298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99(3):459–496. doi: 10.1093/brain/99.3.459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/99.3.459</ArticleId>
            <ArticleId IdType="pubmed">11871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strada O., Vyas S., Hirsch E.C., Ruberg M., Brice A., Agid Y., Javoy-Agid F. Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. Proc. Natl. Acad. Sci. USA. 1992;89(20):9549–9553. doi: 10.1073/pnas.89.20.9549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.89.20.9549</ArticleId>
            <ArticleId IdType="pmc">PMC50169</ArticleId>
            <ArticleId IdType="pubmed">1409664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol. Int. 1999;49(11):921–937. doi: 10.1046/j.1440-1827.1999.00977.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1440-1827.1999.00977.x</ArticleId>
            <ArticleId IdType="pubmed">10594838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesulam M.M. Alzheimer plaques and cortical cholinergic innervation. Neuroscience. 1986;17(1):275–276. doi: 10.1016/0306-4522(86)90242-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(86)90242-3</ArticleId>
            <ArticleId IdType="pubmed">3960313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahiri D.K., Utsuki T., Chen D., Farlow M.R., Shoaib M., Ingram D.K., Greig N.H. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. 2002. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12105112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racchi M., Sironi M., Caprera A., Konig G., Govoni S. Shortand
long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol.
Psychiatry. 2001;6:520–528. doi: 10.1038/sj.mp.4000878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4000878</ArticleId>
            <ArticleId IdType="pubmed">11526466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry. 2001;40(35):10447–10457. doi: 10.1021/bi0101392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi0101392</ArticleId>
            <ArticleId IdType="pubmed">11523986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apelt J., Kumar A., Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res. 2002;953(1-2):17–30. doi: 10.1016/S0006-8993(02)03262-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-8993(02)03262-6</ArticleId>
            <ArticleId IdType="pubmed">12384234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 2008;148(5):379–397. doi: 10.7326/0003-4819-148-5-200803040-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-148-5-200803040-00009</ArticleId>
            <ArticleId IdType="pubmed">18316756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y., Lai M.S., Lu C.J., Chen R.C. How long can patients with mild or moderate Alzheimer’s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur. J. Neurol. 2008;15(3):278–283. doi: 10.1111/j.1468-1331.2007.02049.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2007.02049.x</ArticleId>
            <ArticleId IdType="pubmed">18290848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., Burns A., Dening T., Findlay D., Holmes C., Hughes A., Jacoby R., Jones R., Jones R., McKeith I., Macharouthu A., O’Brien J., Passmore P., Sheehan B., Juszczak E., Katona C., Hills R., Knapp M., Ballard C., Brown R., Banerjee S., Onions C., Griffin M., Adams J., Gray R., Johnson T., Bentham P., Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 2012;366(10):893–903. doi: 10.1056/NEJMoa1106668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1106668</ArticleId>
            <ArticleId IdType="pubmed">22397651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hager K., Baseman A.S., Nye J.S., Brashear H.R., Han J., Sano M., Davis B., Richards H.M. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr. Dis. Treat. 2014;10:391–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3937252</ArticleId>
            <ArticleId IdType="pubmed">24591834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer’s type. Drugs. 2011;71(9):1209–1231. doi: 10.2165/11206380-000000000-00000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11206380-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">21711064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guay D.R. Rivastigmine transdermal patch: role in the management of Alzheimer’s disease. Consult Pharm. 2008;23(8):598–609. doi: 10.4140/TCP.n.2008.598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4140/TCP.n.2008.598</ArticleId>
            <ArticleId IdType="pubmed">19032006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galimberti D., Ghezzi L., Scarpini E. Immunotherapy against amyloid pathology in Alzheimer’s disease. J. Neurol. Sci. 2013;333(1-2):50–54. doi: 10.1016/j.jns.2012.12.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2012.12.013</ArticleId>
            <ArticleId IdType="pubmed">23299047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacobini E., Becker R.E. One hundred years after the discovery of Alzheimer’s disease. A turning point for therapy? J. Alzheimers Dis. 2007;12(1):37–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17851193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsang S.W., Lai M.K., Kirvell S., Francis P.T., Esiri M.M., Hope T., Chen C.P., Wong P.T. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. 2006. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.07.010</ArticleId>
            <ArticleId IdType="pubmed">16129514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA. 1992;89(21):10075–10078. doi: 10.1073/pnas.89.21.10075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.89.21.10075</ArticleId>
            <ArticleId IdType="pmc">PMC50280</ArticleId>
            <ArticleId IdType="pubmed">1359534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258(5080):304–307. doi: 10.1126/science.1411529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1411529</ArticleId>
            <ArticleId IdType="pubmed">1411529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease--the pivotal role of brain M1 receptors. Neurodegener. Dis. 2008;5(3-4):237–240. doi: 10.1159/000113712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000113712</ArticleId>
            <ArticleId IdType="pubmed">18322400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher A., Brandeis R., Bar-Ner R.h., Kliger-Spatz M., Natan N., Sonego H., Marcovitch I., Pittel Z.A.  150(S) and AF267B:
M1 muscarinic agonists as innovative therapies for Alzheimer's
disease. .  J. Mol. Neurosci . 2002;19:145–153. doi: 10.1007/s12031-002-0025-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-002-0025-3</ArticleId>
            <ArticleId IdType="pubmed">12212772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671–682. doi: 10.1016/j.neuron.2006.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2006.01.020</ArticleId>
            <ArticleId IdType="pubmed">16504943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forlenza O.V., Spink J.M., Dayanandan R., Anderton B.H., Olesen O.F., Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm (Vienna) 2000;107(10):1201–1212. doi: 10.1007/s007020070034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s007020070034</ArticleId>
            <ArticleId IdType="pubmed">11129110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., Kane A.S., Bridges T.M., Kennedy J.P., Bradley S.R., Peterson T.E., Ansari M.S., Baldwin R.M., Kessler R.M., Deutch A.Y., Lah J.J., Levey A.I., Lindsley C.W., Conn P.J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008;28(41):10422–10433. doi: 10.1523/JNEUROSCI.1850-08.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1850-08.2008</ArticleId>
            <ArticleId IdType="pmc">PMC2577155</ArticleId>
            <ArticleId IdType="pubmed">18842902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyle C.D., Lachowicz J.E. Orally active and selective benzylidene Ketal M-2 muscarinic receptor antagonists for the treatment of Alzheimer's disease. Drug Dev. Res. 2002;56:310–320. doi: 10.1002/ddr.10084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ddr.10084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Züchner T., Perez-Polo J.R., Schliebs R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J. Neurosci. Res. 2004;77(2):250–257. doi: 10.1002/jnr.20152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.20152</ArticleId>
            <ArticleId IdType="pubmed">15211591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dineley K.T. Beta-amyloid peptide--nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front. Biosci. 2007;12:5030–5038. doi: 10.2741/2445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/2445</ArticleId>
            <ArticleId IdType="pubmed">17569627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S,G., Satlin A., Shannon H.E, Tollefson G.D., Rasmussen K., Bymaster F.P., Hurley D.J., Potter W.Z., Paul S.M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. 1997. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1997.00550160091022</ArticleId>
            <ArticleId IdType="pubmed">9109749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirey J.K., Brady A.E., Jones P.J., Davis A.A., Bridges T.M., Kennedy J.P., Jadhav S.B., Menon U.N., Xiang Z., Watson M.L., Christian E.P., Doherty J.J., Quirk M.C., Snyder D.H., Lah J.J., Levey A.I., Nicolle M.M., Lindsley C.W., Conn P.J. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 2009;29(45):14271–14286. doi: 10.1523/JNEUROSCI.3930-09.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3930-09.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2811323</ArticleId>
            <ArticleId IdType="pubmed">19906975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conn P.J., Jones C.K., Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 2009;30(3):148–155. doi: 10.1016/j.tips.2008.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2008.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC2907736</ArticleId>
            <ArticleId IdType="pubmed">19201489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirey J.K., Xiang Z., Orton D., Brady A.E., Johnson K.A., Williams R., Ayala J.E., Rodriguez A.L., Wess J., Weaver D., Niswender C.M., Conn P.J. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008;4(1):42–50. doi: 10.1038/nchembio.2007.55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2007.55</ArticleId>
            <ArticleId IdType="pubmed">18059262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brady A.E., Jones C.K., Bridges T.M., Kennedy J.P., Thompson A.D., Heiman J.U., Breininger M.L., Gentry P.R., Yin H., Jadhav S.B., Shirey J.K., Conn P.J., Lindsley C.W. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 2008;327(3):941–953. doi: 10.1124/jpet.108.140350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.108.140350</ArticleId>
            <ArticleId IdType="pmc">PMC2745822</ArticleId>
            <ArticleId IdType="pubmed">18772318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B., Yang L., Wang Z., Zheng H. Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc. Natl. Acad. Sci. USA. 2007;104(35):14140–14145. doi: 10.1073/pnas.0704070104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0704070104</ArticleId>
            <ArticleId IdType="pmc">PMC1955810</ArticleId>
            <ArticleId IdType="pubmed">17709753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308. doi: 10.1111/j.1527-3458.2003.tb00254.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1527-3458.2003.tb00254.x</ArticleId>
            <ArticleId IdType="pmc">PMC6741669</ArticleId>
            <ArticleId IdType="pubmed">14530799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenk G.L., Parsons C.G., Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav. Pharmacol. 2006;17(5-6):411–424. doi: 10.1097/00008877-200609000-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00008877-200609000-00007</ArticleId>
            <ArticleId IdType="pubmed">16940762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong W.Y., Tanaka K., Dawe G.S., Ittner L.M., Farooqui A.A. Slow excitotoxicity in Alzheimer’s disease. J. Alzheimers Dis. 2013;35(4):643–668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23481689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiger A., Nordberg A., von Holst H., Bäckman L., Ebendal T., Alafuzoff I., Amberla K., Hartvig P., Herlitz A., Lilja A., et al.  Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav. Brain Res. 1993;57(2):255–261. doi: 10.1016/0166-4328(93)90141-C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-4328(93)90141-C</ArticleId>
            <ArticleId IdType="pubmed">8117429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksdotter Jönhagen M., Nordberg A., Amberla K., Bäckman L., Ebendal T., Meyerson B., Olson L., Seiger S.M., Shigeta M., Theodorsson E., Viitanen M., Winblad B., Wahlund L.O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 1998;9(5):246–257. doi: 10.1159/000017069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000017069</ArticleId>
            <ArticleId IdType="pubmed">9701676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005;11(5):551–555. doi: 10.1038/nm1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1239</ArticleId>
            <ArticleId IdType="pubmed">15852017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W., Wictorin K., Björklund A., Williams L.R., Varon S., Gage F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329(6134):65–68. doi: 10.1038/329065a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/329065a0</ArticleId>
            <ArticleId IdType="pubmed">3627243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geylis V., Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun. Rev. 2006;5(1):33–39. doi: 10.1016/j.autrev.2005.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2005.06.007</ArticleId>
            <ArticleId IdType="pubmed">16338209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408(6815):979–982. doi: 10.1038/35050110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35050110</ArticleId>
            <ArticleId IdType="pubmed">11140685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–985. doi: 10.1038/35050116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35050116</ArticleId>
            <ArticleId IdType="pubmed">11140686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177. doi: 10.1038/22124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/22124</ArticleId>
            <ArticleId IdType="pubmed">10408445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bales K.R., Tzavara E.T., Wu S., Wade M.R., Bymaster F.P., Paul S.M., Nomikos G.G. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J. Clin. Invest. 2006;116(3):825–832. doi: 10.1172/JCI27120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI27120</ArticleId>
            <ArticleId IdType="pmc">PMC1378188</ArticleId>
            <ArticleId IdType="pubmed">16498501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M., AN1792(QS-21)-201 Study Team  Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–1562. doi: 10.1212/01.WNL.0000159740.16984.3C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000159740.16984.3C</ArticleId>
            <ArticleId IdType="pubmed">15883316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., DeMattos R.B., Mohs R., Paul S.M., Siemers E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8(4):261–271. doi: 10.1016/j.jalz.2011.09.224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.09.224</ArticleId>
            <ArticleId IdType="pubmed">22672770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., Seubert P., Schenk D., Holmes C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006;65(11):1040–1048. doi: 10.1097/01.jnen.0000240466.10758.ce.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jnen.0000240466.10758.ce</ArticleId>
            <ArticleId IdType="pubmed">17086100</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
